|
COPYRIGHT 2004 International Medical News Group
SNOWMASS, COLO. -- Current treatment options for psoriatic arthritis--and the wealth of drugs in the developmental pipeline were unimaginable just 5 years ago, Dr. Christopher T. Ritchlin observed at a symposium sponsored by the American College of Rheumatology.
Topping the list of new therapeutics is etanercept. It is the sole Food and Drug Administration-approved treatment for psoriatic arthritis, so a case can be made for using the tumor necrosis factor (TNF) blocker as first-line therapy rather than reserving it for methotrexate failures, as most physicians now do, said Dr. Ritchlin, director of the clinical immunology research...
Read the full article for free courtesy of your local library.
| 
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
